A logic‑gated trispecific engager designed to direct macrophages against solid tumor cells showed enhanced antitumor activity in preclinical models. Published in Nature Biotechnology, the work describes a trispecific molecule that binds tumor antigen(s) while simultaneously engaging macrophage effector mechanisms to increase phagocytosis and cytotoxicity. The paper provides evidence that multispecific designs can overcome macrophage‑mediated suppression in the tumor microenvironment and improve clearance of solid malignancies. Sponsors and CDMOs will now evaluate manufacturability, safety, and translational biomarkers as part of preclinical development and potential IND enabling programs.